Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by Fastlane2on Jan 16, 2013 5:26pm
205 Views
Post# 20847308

Bravo

Bravo

I'm in the positive camp on this one, yes I am a long term shareholder and a true believer. This is a very clear message to Aurizon or Alamos that the deposit is real and growing. Aurizon has had it's own frustration's and distraction's so Niogold delivering this news release on it's own accord is good. I don't believe Aurizon has had the privilege to see the phase two results and I don't believe that they are sitting tight contemplating what to do next, they have a history of poor decision making and waiting to long to advance any venture, hence the CEO change in 2009 unfortunately this new Aurizon CEO barks the same tune. Aurizon's stock chart for the last three years is proof of a roller coaster ride it's sent it's shareholders thus the Alamos offer, which I feel is opportunistic. Here is to a change of direction, with or without Aurizon. GL.

 

Fastlane

<< Previous
Bullboard Posts
Next >>